Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511–21.

Article  PubMed  Google Scholar 

Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84.

Article  PubMed  Google Scholar 

Zhang S, Peng L, Li Q, Zhao J, Xu D, Zhao J, et al. Spectrum of spondyloarthritis among Chinese populations. Curr Rheumatol Rep. 2022;24(8):247–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383–91.

Article  PubMed  PubMed Central  Google Scholar 

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34.

Article  PubMed  Google Scholar 

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285–99.

Article  PubMed  Google Scholar 

Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewé RBM, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023;82(1):130–41.

Article  CAS  PubMed  Google Scholar 

Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1(1): e000017.

Article  PubMed  PubMed Central  Google Scholar 

Baraliakos X, Szumski A, Koenig AS, Jones H. The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. Semin Arthritis Rheum. 2019;48(6):997–1004.

Article  CAS  PubMed  Google Scholar 

Wang R, Dasgupta A, Ward MM. Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw Open. 2022;5(3): e222312.

Article  PubMed  PubMed Central  Google Scholar 

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16-week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–51.

Article  PubMed  Google Scholar 

Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176–85.

Article  CAS  PubMed  Google Scholar 

Maksymowych WP, Bolce R, Gallo G, Seem E, Geneus VJ, Sandoval DM, et al. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging. Rheumatology (Oxford). 2022;61(11):4324–34.

Article  CAS  PubMed  Google Scholar 

Xue Y, Hu J, Liu D, Li J, Wu H, Tan C, et al. Ixekizumab for active radiographic axial spondyloarthritis in Chinese patients: 16- and 52-week results from a phase III, randomized, double-blind, placebo-controlled study. BioDrugs. 2024;38(1):145–56.

Article  CAS  PubMed  Google Scholar 

Sengupta R. Machado PM, Goupille P, Navarro Compán V, Huji X, Sheesh M, Jing Ng K, Ngantcha M, Russ H, Doridot G, Baraliakos X. Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial [abstract]. Arthritis Rheumatol. 2024;76(suppl 9). Available from: https://acrabstracts.org/abstract/baseline-characteristics-and-efficacy-in-patients-with-radiographic-axspa-r-axspa-stratified-by-crp-level-an-analysis-from-the-ixekizumab-phase-iii-trial/. Accessed Dec 2024.

van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811–8.

Article  PubMed  Google Scholar 

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.

CAS  PubMed  Google Scholar 

Braun J, Deodhar A, Landewé R, Baraliakos X, Miceli-Richard C, Sieper J, et al. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open. 2018;4(2): e000749.

Article  PubMed  PubMed Central  Google Scholar 

Reveille J RP, Sandoval D, Muran T, Kronbergs A, Bolce R, Geneus V, Hunter T, Liu-Leage S, Rudwaleit M, Maldonado-Cocco J, Van den Bosch F. Response to Ixekizumab by C-reactive protein level in patients with radiographic axial spondyloarthritis: results from the COAST-V (biological-naïve) and COAST-W (TNF inhibitor-experienced) trials at 52 weeks. In: Poster presented at the American College of Rheumatology convergence, November 5–9, 2020 (all virtual); abstract 0904. Available from: https://acrabstracts.org/abstract/response-to-ixekizumab-by-c-reactive-protein-level-in-patients-with-radiographic-axial-spondyloarthritis-results-from-the-coast-v-biological-naive-and-coast-w-tnf-inhibitor-experienced-trials-at/. Accessed Dec 2024.

de Vlam K, Maksymowych WP, Gallo G, Rahman P, Mease P, Krishnan V, et al. Exploring the effects of ixekizumab on pain in patients with ankylosing spondylitis based on objective measures of inflammation: post hoc analysis from a large randomized clinical trial. Rheumatol Ther. 2024;11(3):691–707.

Article  PubMed  PubMed Central  Google Scholar 

Zhu X, Hu J, Liu D, Li J, Wu H, Sun L, et al. Rapid and sustained effect of ixekizumab on patient global, spinal pain, stiffness, and fatigue in Chinese patients with radiographic axial spondyloarthritis. Rheumatol Ther. 2024;11(4):1011–22.

Maksymowych WP. Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front Immunol. 2019;10:305.

Article  CAS  PubMed  PubMed Central  Google Scholar